- Home
- NML vs RLAY Comparison
NML vs RLAY Comparison
Compare NML & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NML
- RLAY
- Stock Information
- Founded
- NML 2012
- RLAY 2015
- Country
- NML United States
- RLAY United States
- Employees
- NML N/A
- RLAY N/A
- Industry
- NML Finance/Investors Services
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NML Finance
- RLAY Health Care
- Exchange
- NML Nasdaq
- RLAY Nasdaq
- Market Cap
- NML 488.4M
- RLAY 803.4M
- IPO Year
- NML N/A
- RLAY 2020
- Fundamental
- Price
- NML $8.15
- RLAY $7.10
- Analyst Decision
- NML
- RLAY Strong Buy
- Analyst Count
- NML 0
- RLAY 8
- Target Price
- NML N/A
- RLAY $17.25
- AVG Volume (30 Days)
- NML 219.3K
- RLAY 1.8M
- Earning Date
- NML 01-01-0001
- RLAY 11-07-2025
- Dividend Yield
- NML 9.75%
- RLAY N/A
- EPS Growth
- NML N/A
- RLAY N/A
- EPS
- NML N/A
- RLAY N/A
- Revenue
- NML N/A
- RLAY $8,355,000.00
- Revenue This Year
- NML N/A
- RLAY $27.33
- Revenue Next Year
- NML N/A
- RLAY $7.40
- P/E Ratio
- NML N/A
- RLAY N/A
- Revenue Growth
- NML N/A
- RLAY N/A
- 52 Week Low
- NML $6.09
- RLAY $1.78
- 52 Week High
- NML $7.33
- RLAY $7.50
- Technical
- Relative Strength Index (RSI)
- NML 40.06
- RLAY 68.24
- Support Level
- NML $7.89
- RLAY $6.30
- Resistance Level
- NML $8.37
- RLAY $7.18
- Average True Range (ATR)
- NML 0.19
- RLAY 0.51
- MACD
- NML -0.01
- RLAY 0.01
- Stochastic Oscillator
- NML 32.91
- RLAY 81.98
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).